Early cost-utility analysis of genetically guided therapy for patients with drug-resistant epilepsy.

This early economic evaluation of a pharmacogenomics panel to guide treatment for drug-resistant epilepsy could potentially be cost-effective in the Australian health care system. Clinical trial evidence is necessary to confirm these findings.